Adipose Tissue-Derived Stromal/Stem Cells Transplantation with Cholecalciferol Supplementation in Recent-Onset Type 1 Diabetes Patients: Twelve Months Follow-Up
Horm Metab Res DOI: 10.1055/a-2094-1039To evaluate safety and therapeutic effect along 12 months of allogenic adipose
tissue-derived stromal/stem cells (ASCs) transplantation with
cholecalciferol (VITD) in patients with recent-onset type 1 diabetes (T1D).
Prospective, phase II, open trial, pilot study in which patients with recent
onset T1D received ASCs (1xKgx106 cells) and VITD 2000UI/day
for 12 months (group 1) and were compared to controls with standard insulin
therapy (group 2). Adverse events, C-peptide area under the curve (CPAUC),
insulin dose, HbA1c and frequency of FoxP3+ in CD4+ or
CD8+ T-cells(flow cytometry) were evaluated at baseline(T0), after
3(T3), 6(T6) and 12 months(T12). Eleven patients completed follow up (7:group
1;4:group 2). Group 1 had lower insulin requirement at
T3(0.24±0.18vs0.53±0.23UI/kg,p=0.04),
T6(0.24±0.15vs0.66±0.33 UI/kg,p=0.04) and
T12(0.39±0.15vs0.74±0.29 UI/Kg,p=0.04).HbA1c was
lower at T6
(50.57±8.56vs72.25±10.34 mmol/mol,p=0.01),
without differences at T12 (57.14±11.98 in group 1 vs.
73.5±14.57 mmol/min in group 2, p=0.16). CPAUC
was not significantly different between groups at T0(p=0.07), higher in
group 1 at T3(p=0.04) and T6(p=0.006), but similar at
T12(p=0.23). IDAA1c was significantly lower in group 1 than group 2 at
...
Source: Hormone and Metabolic Research - Category: Endocrinology Authors: Dantas, Joana R. Araujo, Debora Batista Silva, Karina Ribeiro Souto, Debora Lopes Pereira, Maria de Fatima Carvalho Raggio, Luiz Ronir Claudio-da Silva, Cesar Couri, Carlos Eduardo Maiolino, Angelo Rebellato, Carmen Lucia Kuniyoshi Daga, Debora Regina Sen Tags: Original Article: Endocrine Care Source Type: research
More News: Diabetes | Diabetes Type 1 | Endocrinology | Hormones | Insulin | Pancreas | Stem Cell Therapy | Stem Cells | Study | Teratoma | Transplants | Vitamin D3